Uncertainty and the value of diagnostic information, with application to axillary lymph node dissection in breast cancer

In clinical decision making, it is common to ask whether, and how much, a diagnostic procedure is contributing to subsequent treatment decisions. Statistically, quantification of the value of the information provided by a diagnostic procedure can be carried out using decision trees with multiple decision points, representing both the diagnostic test and the subsequent treatments that may depend on the test's results. This article investigates probabilistic sensitivity analysis approaches for exploring and communicating parameter uncertainty in such decision trees. Complexities arise because uncertainty about a model's inputs determines uncertainty about optimal decisions at all decision nodes of a tree. We present the expected utility solution strategy for multistage decision problems in the presence of uncertainty on input parameters, propose a set of graphical displays and summarization tools for probabilistic sensitivity analysis in multistage decision trees, and provide an application to axillary lymph node dissection in breast cancer.

[1]  M. Silverstein,et al.  Axillary lymph node dissection for t1a breast carcinoma. Is it indicated? , 1994, Cancer.

[2]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[3]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[4]  F. Cavalli,et al.  Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer , 1991 .

[5]  Howard Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .

[6]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[7]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[8]  R. Clemen,et al.  Soft Computing , 2002 .

[9]  B. McNeil,et al.  Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  K E Willard,et al.  Probabilistic sensitivity analysis methods for general decision models. , 1986, Computers and biomedical research, an international journal.

[11]  M. Weinstein,et al.  Clinical Decision Analysis , 1980 .

[12]  A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study , 1985, World Journal of Surgery.

[13]  Eric R. Ziegel,et al.  Modeling in Medical Decision Making , 2002, Technometrics.

[14]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[15]  Peter Green,et al.  Markov chain Monte Carlo in Practice , 1996 .

[16]  J Lipscomb,et al.  Assessing Uncertainty in Cost-Effectiveness Analyses , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[18]  George Schlesinger,et al.  Location and Range , 1990, The British Journal for the Philosophy of Science.

[19]  R. Epstein Routine or delayed axillary dissection for primary breast cancer? , 1995, European journal of cancer.

[20]  N. Sahlin Weight of the Value of Knowledge , 1990 .

[21]  D. Berry,et al.  Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[23]  K. Kuntz,et al.  A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. , 1999, Surgery.

[24]  D W Kinne,et al.  Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. , 1996, Important advances in oncology.

[25]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[26]  K E Willard,et al.  Probabilistic Analysis of Decision Trees Using Monte Carlo Simulation , 1986, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  Lee B. Lusted,et al.  Introduction to medical decision making , 1968 .

[28]  E. Winer,et al.  Complications of axillary lymph node dissection for carcinoma of the breast , 1998, Cancer.

[29]  A. Recht,et al.  Axillary lymph nodes and breast cancer. A review , 1995, Cancer.

[30]  B. Cady Is Axillary Lymph Node Dissection Necessary in Routine Management of Breast Cancer? No. , 1997, Important advances in oncology.

[31]  H. Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .

[32]  David J. Pasta,et al.  Probabilistic Sensitivity Analysis Incorporating the Bootstrap , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[33]  Morris H. Degroot,et al.  Changes in utility as information , 1994 .

[34]  V. Velanovich Axillary lymph node dissection for breast cancer: A decision analysis of T1 lesions , 1998, Annals of Surgical Oncology.

[35]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[36]  L. Norton,et al.  Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Saigo,et al.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.